The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN8920     N-phenylquinazolin-4-amine

Synonyms: Kinome_2867, CHEMBL289959, Enamine_003240, NSC-288013, Oprea1_243645, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of N-phenylquinazolin-4-amine

  • Previously, 4-anilinoquinazoline TKIs have been shown to inhibit the function of the breast cancer resistance-associated drug transporter (ABCG2), reversing resistance to camptothecin derivatives topotecan and SN-38 [1].

High impact information on N-phenylquinazolin-4-amine


Biological context of N-phenylquinazolin-4-amine


Anatomical context of N-phenylquinazolin-4-amine


Associations of N-phenylquinazolin-4-amine with other chemical compounds


Gene context of N-phenylquinazolin-4-amine


  1. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Houghton, P.J., Germain, G.S., Harwood, F.C., Schuetz, J.D., Stewart, C.F., Buchdunger, E., Traxler, P. Cancer Res. (2004) [Pubmed]
  2. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Zhou, Y., Li, S., Hu, Y.P., Wang, J., Hauser, J., Conway, A.N., Vinci, M.A., Humphrey, L., Zborowska, E., Willson, J.K., Brattain, M.G. Cancer Res. (2006) [Pubmed]
  3. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Leggas, M., Panetta, J.C., Zhuang, Y., Schuetz, J.D., Johnston, B., Bai, F., Sorrentino, B., Zhou, S., Houghton, P.J., Stewart, C.F. Cancer Res. (2006) [Pubmed]
  4. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. Blencke, S., Ullrich, A., Daub, H. J. Biol. Chem. (2003) [Pubmed]
  5. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. Shewchuk, L., Hassell, A., Wisely, B., Rocque, W., Holmes, W., Veal, J., Kuyper, L.F. J. Med. Chem. (2000) [Pubmed]
  6. Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases. Baguley, B.C., Marshall, E.S., Holdaway, K.M., Rewcastle, G.W., Denny, W.A. Eur. J. Cancer (1998) [Pubmed]
  7. 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Assefa, H., Kamath, S., Buolamwini, J.K. J. Comput. Aided Mol. Des. (2003) [Pubmed]
  8. Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors. Hennequin, L.F., Ballard, P., Boyle, F.T., Delouvrié, B., Ellston, R.P., Halsall, C.T., Harris, C.S., Hudson, K., Kendrew, J., Pease, J.E., Ross, H.S., Smith, P., Vincent, J.L. Bioorg. Med. Chem. Lett. (2006) [Pubmed]
  9. 1,4-dioxane-fused 4-anilinoquinazoline as inhibitors of epidermal growth factor receptor kinase. Lee, J.Y., Park, Y.K., Seo, S.H., So, I.S., Chung, H.K., Yang, B.S., Lee, S.J., Park, H., Lee, Y.S. Arch. Pharm. (Weinheim) (2001) [Pubmed]
  10. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41. Matheson, S.L., McNamee, J.P., Jean-Claude, B.J. Cancer Chemother. Pharmacol. (2003) [Pubmed]
  11. The tyrosine kinase inhibitor PD153035: implication of labeling position on radiometabolites formed in vitro. Sam??n, E., Thorell, J.O., Fredriksson, A., Stone-Elander, S. Nucl. Med. Biol. (2006) [Pubmed]
  12. High performance liquid chromatography analysis of a 4-anilinoquinazoline derivative (PD153035), a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in rat plasma. Rocco, S.A., Velho, J.A., Marin, R.M., de Arruda Rolim Filho, L., Vercesi, A.E., Rittner, R., Franchini, K.G. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2005) [Pubmed]
WikiGenes - Universities